Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06278766 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06278766 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 8 participants.
The verdict
NCT06278766, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-552 in healthy, male volunteers following administration of a single oral dose.
Interventions
- DRUG ABBV-552
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06278766
The ClinicalTrials.gov registry entry for NCT06278766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABBV-552 is the first listed.
NCT06278766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06278766 about?
NCT06278766 is a clinical study titled "A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration". The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-552 in healthy, male volunteers following administration of a single oral dose.
What is the current status of trial NCT06278766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-02-21. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT06278766?
The interventions under investigation include: ABBV-552 (DRUG).
Who is sponsoring clinical trial NCT06278766?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.